Approach

Summary

Licensing status

Publication and contact information

Assays & screens

Profiling tumor-derived microvesicles in the blood of patients with glioblastoma multiforme (GBM)

A microfluidic system for profiling tumor-derived microvesicles in the blood of patients with GBM could help guide treatment decisions. On a microfluidic chip, microvesicles were first labeled with a protein-targeted antibody conjugated to a magnetic nanoparticle and then detected by micro-NMR. The assay was able to distinguish between blood samples from patients with GBM and those from healthy volunteers with 90% accuracy based on the expression of four protein markers on microvesicles. In patients with GBM treated with Temodar temozolomide, changes in microvesicle numbers and biomarker expression could be used to distinguish responders from nonresponders. Next steps include expanding the approach to other tumor types and developing a platform for comprehensive analysis of microvesicle biomarkers, including proteins, mRNAs and microRNAs.
Merck & Co. Inc. markets Temodar to treat GBM.

SciBX 5(47); doi:10.1038/scibx.2012.1242
Published online Dec. 6, 2012

Patent application filed on the micro-NMR system; unavailable for licensing

Shao, H. et al. Nat. Med.; published online Nov. 11, 2012;
doi:10.1038/nm.2994
Contact: Ralph Weissleder, Massachusetts General Hospital, Boston, Mass.
e-mail:

rweissleder@mgh.harvard.edu
Contact: Hakho Lee, same affiliation as above
e-mail:

hlee@mgh.harvard.edu